Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Understanding interactions occurring at the interface between nanoparticles and biological components is an urgent challenge in nanomedicine due to their effect on the biological fate of nanoparticles. After the systemic injection of nanoparticles, a protein corona constructed by blood components surrounds the carrier's surface and modulates its pharmacokinetics and biodistribution. Biomimicry-based approaches in nanotechnology attempt to imitate what happens in nature in order to transfer specific natural functionalities to synthetic nanoparticles. Several biomimetic formulations have been developed, showing superior in vivo features as a result of their cell-like identity. We have recently designed biomimetic liposomes, called leukosomes, which recapitulate the ability of leukocytes to target inflamed endothelium and escape clearance by the immune system. To gain insight into the properties of leukosomes, we decided to investigate their protein corona in vivo. So far, most information about the protein corona has been obtained using in vitro experiments, which have been shown to minimally reproduce in vivo phenomena. Here we directly show a time-dependent quantitative and qualitative analysis of the protein corona adsorbed in vivo on leukosomes and control liposomes. We observed that leukosomes absorb fewer proteins than liposomes, and we identified a group of proteins specifically adsorbed on leukosomes. Moreover, we hypothesize that the presence of macrophage receptors on leukosomes' surface neutralizes their protein corona-meditated uptake by immune cells. This work unveils the protein corona of a biomimetic carrier and is one of the few studies on the corona performed in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“these strategies are still limited at conferring targeting specificity since an additional targeting ligand increases the propensity for protein corona formation to mask the targeting ability and inhibit the biological effects of nanoparticles18–24.”
From Cloaking nanoparticles with protein corona shield for targeted drug delivery. (2018) · cites this paper as [20]
In the citing paper
“suggesting that PCSN can increase their circulation time in the blood by decreasing the uptake from the immune system20.”
From Cloaking nanoparticles with protein corona shield for targeted drug delivery. (2018) · cites this paper as [20]
In the citing paper
“A critical but underexplored determinant of LNP biodistribution is the protein corona, the dynamic layer of plasma proteins adsorbed onto nanoparticle surfaces upon entry into the bloodstream, which fundamentally dictates receptor interactions, cellular uptake pathways, and organ-level distribution [20][21][22] .”
From High-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain (2026) · cites this paper as [20]
Citations
Cites
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Harrison’s Principles of Internal Medicine
Malani, P. N. (2012) · JAMA · doi:10.1001/jama.308.17.1813-b · Cited by 2,039
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Research works printed but not linked: 2
- Langer R., 1998, Nature, 392, 5
- Lee H., 1985, J. Nucl. Med., 26, 72
Cited by
Items 101–154 of 154
Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy
Yang, W., Lin, P., Gao, R., Fang, Z., Wang, Z., Ma, Z., Shi, J., & Yu, W.-Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101332 · Cited by 17
Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle‐Based Gene Delivery Systems
Greco, A., & Corbo, C. (2025) · Small Science · doi:10.1002/smsc.202500206 · Cited by 13
Self-citationWen, X., Ou, L., Cutshaw, G., Uthaman, S., Ou, Y., Zhu, T., Szakas, S. E., Carney, B. D., Houghton, J. L., Gundlach‐Graham, A., et al. (2023) · Small · doi:10.1002/smll.202204293 · Cited by 13
Fukuta, T., Yoshimi, S., & Kogure, K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.049 · Cited by 13
Wang, X., Gong, J., Tan, W., Hu, T., Rong, R., Gui, Z., Nie, K., & Xu, X. (2020) · Nanoscale · doi:10.1039/d0nr06315k · Cited by 12
Chen, L., Deng, X., Shen, Q., Chen, M., Li, C., & Wang, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s559763 · Cited by 21
“60,61 64 A second major obstacle is the extremely low accumulation of passively targeted nanoparticles in solid tumors: Wilhem et al conducted a literature review and calculated that only approximately 0.7% of injected nanoparticles accumulate in solid tumors in mice, a median value that, while not…”
InfluentialBattaglini, M., Gümüş, M. B., & Ciofani, G. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202100660 · Cited by 11
Translating Current Bioanalytical Techniques for Studying Corona Activity
Wang, C., Wang, Z., & Dong, L. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.02.016 · Cited by 11
Laser irradiation affects the biological identity and cellular uptake of plasmonic nanoparticles
Hashemi, F., Hormozi-Nezhad, M. R., Corbo, C., Farvadi, F., Shokrgozar, M. A., Mehrjoo, M., Atyabi, F., Ghahremani, M. H., Mahmoudi, M., & Dinarvand, R. (2019) · Nanoscale · doi:10.1039/c8nr09622h · Cited by 11
Self-citationLong circulating nanocarriers: achievements and shortcomings of biomimetic approaches
Boushehri, M. A. S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126488 · Cited by 14
Jang, G. J., Jeong, J. Y., Joung, H., & Han, S. Y. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113488 · Cited by 10
Jaiswal, N., Mahata, N., & Chanda, N. (2025) · Nanoscale · doi:10.1039/d4nr05279j · Cited by 14
The nanoparticle protein corona impacts interactions with monocytes and macrophages
Lins, A., Fortmann, M., Mulac, D., Humpf, H., & Langer, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126518 · Cited by 11
Wang, F., Hou, W., Xiao, C., Hao, Y., Su, N., Deng, Y. L., Wang, J., Yu, L., Xie, J.-M., Xiong, J., et al. (2021) · Nanoscale · doi:10.1039/d1nr04181a · Cited by 9
A Bird’s Eye View of Various Cell-Based Biomimetic Nanomedicines for the Treatment of Arthritis
Vasdev, N., Pawar, B., Gupta, T., Mhatre, M., & Tekade, R. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041150 · Cited by 10
“c ti f i l c l s t t f r s t s rf c f rticl s t r istri te i i l ical fl i s ai s i t e a s r ti f certai r tei s t at el i acti e targeti g [107].”
BackgroundJin, X., Wu, H., Yu, J., Cao, Y., Zhang, L., Zhang, Z., & Lv, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.013 · Cited by 9
Rui, X., Okamoto, Y., Watanabe, N. M., Shimizu, T., Wakileh, W., Kajimura, N., & Umakoshi, H. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01063a · Cited by 9
Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma
Giordano, F., Lenna, S., Baudo, G., Rampado, R., Massaro, M., Rosa, E. D., Ewing, A., Kurenbekova, L., Agostini, M., Yustein, J. T., et al. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00146-7 · Cited by 8
Self-citationProtein Corona Sensor Array Nanosystem for Detection of Coronary Artery Disease
Lee, G. Y., Li, A. A., Moon, I., Katritsis, D., Pantos, Y., Stingo, F. C., Fabbrico, D., Molinaro, R., Taraballi, F., Tao, W., et al. (2023) · Small · doi:10.1002/smll.202306168 · Cited by 9
Self-citationPre-programming the protein corona: From avoidance to endogenous targeting
Kumari, N. U., Chigurupati, S. P. D., Rajana, N., Vasave, R., Bahadure, S. D., & Mehra, N. K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114447 · Cited by 10
Progress and Hurdles of Therapeutic Nanosystems against Cancer
Martín-Contreras, M., Navarro-Marchal, S. A., Peula-García, J. M., & Jódar‐Reyes, A. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020388 · Cited by 11
Kumar, V., & Gupta, U. D. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104466 · Cited by 8
Antonio, L. C., Ribovski, L., Lins, P. M. P., & Zucolotto, V. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01296k · Cited by 9
Jeong, J. Y., Joung, H., Jang, G. J., & Han, S. Y. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12692 · Cited by 7
Mancino, C., Pastò, A., Rosa, E. D., Dolcetti, L., Rasponi, M., McCulloch, P. C., & Taraballi, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16640 · Cited by 7
Self-citationLiu, Z., Zhan, X., Xu, X., Wu, Y., & Gu, Z. (2018) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201700418 · Cited by 8
Quantifying Vascular Distribution and Adhesion of Nanoparticles with Protein Corona in Microflow
Ho, Y. T., Lee, S. W. L., Azman, N. ‘., Loh, F. W. Y., Thien, N. P., & Kah, J. C. Y. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b00322 · Cited by 7
Liu, D., Yu, J., Li, J., Chen, Y., Peng, M., Xu, Y., Wu, Y., Ding, L., & He, S. (2026) · Advanced Science · doi:10.1002/advs.202519127 · Cited by 10
Fundamentals behind the success of nanotechnology in cancer treatment and diagnosis
Chowdhury, M. M. H., Kubra, K., & Islam, A. (2024) · OpenNano · doi:10.1016/j.onano.2024.100215 · Cited by 6
Next generation nanoparticle protein corona characterization methods
He, W., Wu, W., Li, Y., Liu, Q., Ren, P., Liu, H., & Chen, F. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2460962 · Cited by 5
Plasmonic Material Engineering for Targeted Therapeutics
Florentsen, C. D., Moreno-Pescador, G., Kjær, A., Oddershede, L. B., & Bendix, P. M. (2020) · Advanced Optical Materials · doi:10.1002/adom.202000616 · Cited by 5
Surmounting the endothelial barrier for delivery of drugs and imaging tracers
Schnitzler, J. G., Dzobo, K. E., Nurmohamed, N. S., Stroes, E. S. G., & Kroon, J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.025 · Cited by 8
Drug-free Immunotherapeutic Biomimetic Nanoparticles for Treating Triple-Negative Breast Cancer
Vizenblit, O., Mhajne, R., & Zinger, A. (2026) · ACS Nano · doi:10.1021/acsnano.5c18774 · Cited by 6
“Our findings, consistent with previous studies, 14 revealed that integrating macrophage membrane proteins into the MPsome bilayer affected the protein corona formation, resulting in significant size growth only after 24 h of incubation.”
InfluentialZhang, X., Yao, Y., Jiang, Y., Liao, J., Yang, R., Deng, X., & Zhang, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122764 · Cited by 4
“However, traditional nanocarriers for drug delivery suffer from inherent drawbacks, such as poor exogenetic origin and biocompatibility [12,13] and short half-lives [14].”
BackgroundLiposomes as “Trojan Horses” in Cancer Treatment: Design, Development, and Clinical Applications
Sabín, J., Santisteban-Veiga, A., Costa-Santos, A., Abelenda, Ó., & Domínguez-Arca, V. (2025) · Lipidology · doi:10.3390/lipidology2040025 · Cited by 4
“For example, leukosomes, which combine leukocyte membranes with liposomes, exhibit longer circulation times and greater accumulation in inflamed tissues [150].”
He, T., Fang, X., Zhu, L., Fan, H., Qiu, Y., Zhou, L., & Jiang, S. (2026) · Small · doi:10.1002/smll.73301 · Cited by 3
Preadsorbed Chymotrypsin Modulated the Composition of Protein Corona and Immunological Response
Han, L., Wang, Y., Jia, H., Zhang, Z., Yang, S., Li, F., Li, F., & Yang, H. (2024) · ACS Omega · doi:10.1021/acsomega.3c08288 · Cited by 4
“7,,12 However, the natural corona formed by unconditional contact between NPs and plasma proteins has a variable impact on macrophage polarization due to the instability of protein corona components.”
BackgroundPelle, G. D., Markelc, B., Čerček, U., Živič, U., Coupard, M., Šribar, J., Križaj, I., Arshad, M. S., Božič, T., Gazvoda, L., et al. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214537 · Cited by 4
Flexibility in the Design of Nanomedicine Using Biomimetic Immunomodulatory
Patil, A. S., Masareddy, R. S., & Patil, P. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-35395-6_9 · Cited by 2
Mohammadi, M. R., Luong, J. C., Kim, G. G., Lau, H., & Lakey, J. R. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102563-5.00007-1 · Cited by 3
Grundler, J., Shin, K., Suh, H., Whang, C., & Saltzman, W. M. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-s1460 · Cited by 2
Protein Corona of Nanoparticles and Its Application in Drug Delivery
Zhang, W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5386-8_9 · Cited by 3
High-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain
Xu, Z., Shalin, K., Do, V., Yan, A., & Gao, J. (2026) · doi:10.64898/2026.05.29.728695 · Cited by 1
“…but underexplored determinant of LNP biodistribution is the protein corona, the dynamic layer of plasma proteins adsorbed onto nanoparticle surfaces upon entry into the bloodstream, which fundamentally dictates receptor interactions, cellular uptake pathways, and organ-level distribution 20-22 .”
Liu, M., & Lu, W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_3
Antonio, L. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.76.2023.tde-15032023-145008
Qu, H., Jin, X., Cheng, W., Wu, D., Ma, B., Lou, C., Zheng, J., Jing, L., Xue, X., & Wang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22774373
Wu, J., Li, Y.-J., Wang, J., Hu, X., Huang, S., Luo, S., & 向大雄 (2021) · Figshare · doi:10.6084/m9.figshare.17133043
Elaboration de nanoparticules inorganiques pour l’étude des interactions nanoparticules-protéines
Marets, C. (2023) · theses.fr (ABES) · doi:10.70675/134c9238ze110z4d2bz8c37z3b3f3fa1fc18
A comprehensive review of nanotechnology based drug delivery systems for osteoarthritis treatment
Adikari, C., Khan, I., Cho, J., Yoo, S., & Reddy, N. V. (2026) · Nanotechnology Reviews · doi:10.1515/ntrev-2025-0272
“However, due to their optimal biocompatibility and antigenicity, these polymeric materials can activate immunological responses and generate a protein corona [236].”
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Greco, A., Baretta, R., Fonzo, A. D., Armirotti, A., Cinti, S., Mirasoli, M., Frasconi, M., & Corbo, C. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71441
“When introduced into plasma, NPs quickly bind with proteins and other biomolecules to form a dynamic layer known as the biomolecular corona (BC) [17–21].”
Self-citationSaikia, T. (2026) · Biomaterials and Living Medicine for Pharmaceutics · doi:10.1016/j.bioliv.2026.100005 · Cited by 1
Eriksen, K., Berg, S., & Dahl, M. (2025) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/qvyucebgyc
Pasquale, D. D., Patrucco, M., Gumus, M. B., Flori, A., Menichetti, L., Moscato, S., Bonanni, V., Gianoncelli, A., Žižić, M. V., Fiaschi, P., et al. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.70168
Metadata
- Authors
- Corbo, C., Molinaro, R., Taraballi, F., Toledano Furman, N. E., Hartman, K. A., Sherman, M. B., De Rosa, E., Kirui, D. K., Salvatore, F., & Tasciotti, E.
- Affiliations
- CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT)
- Houston Methodist (US)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Corbo, Claudia
- Tasciotti, Ennio
- ORCID
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-03-10
- Volume
- 11
- Issue
- 3
- Pages
- 3262-3273
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2592013183
- Cited by
- 155
- References
- 53
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 5 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 26 · 2019: 17 · 2018: 16 · 2017: 7
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Nano (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- Funders
- European Regional Development Fund
- Hearst Foundations (18130017)
- Ministero della Salute (RF-2010-2305526, RF-2010-2318372)
- Cancer Prevention and Research Institute of Texas (RP170466)
- European Social Fund
- Brown Foundation (18130011)
- Regione Campania
- Cullen Trust for Healthcare (18130014)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- protein corona, biomimetic liposomes, nanoparticle-biomolecule interactions, macrophage receptors, nanoparticle biodistribution, nanoparticle pharmacokinetics, nanomedicine
- MeSH terms
- Protein Corona, Adsorption, Animals, Cell Line, Liposomes, Mass Spectrometry, Microscopy, Confocal, Electrophoresis, Capillary, Cryoelectron Microscopy, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.